Page last updated: 2024-08-21

cyproterone acetate and Soft Tissue Neoplasms

cyproterone acetate has been researched along with Soft Tissue Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Collette, L; de Reijke, TM; Schröder, FH	1

Trials

1 trial(s) available for cyproterone acetate and Soft Tissue Neoplasms

Article	Year
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). European urology, 2003, Volume: 44, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis	2003

Article

Year

Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).

European urology, 2003, Volume: 44, Issue:2

Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cyproterone Acetate; Disease Progression; Flutamide; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis

2003